RecruitingPhase 3NCT07015190

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Studying Uveal melanoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: IDEAYA Biosciences
Intervention: Darovasertib(drug)
Enrollment: 520 enrolled
Eligibility: 18 years · All sexes
Timeline: 2026 – 2031

Study locations (30)

Mayo Clinic Scottsdale - PPDS, Scottsdale, Arizona, United States
UCSD Moores Cancer Center, La Jolla, California, United States
Jules Stein Eye Institute, Los Angeles, California, United States
University of California Irvine Medical Center, Orange, California, United States
Stanford Comprehensive Cancer Center, Palo Alto, California, United States
Kaiser Permanente-Riverside Medical Center, Riverside, California, United States
University of Colorado Hospital, Aurora, Colorado, United States
The Melanoma and Skin Cancer Institute, Englewood, Colorado, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
USF Health Eye Institute, Tampa, Florida, United States
Wilmer Eye Institute, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
W Kellogg Eye Center, Ann Arbor, Michigan, United States
The Cancer and Hematology Centers of West Michigan (CHCWM), Grand Rapids, Michigan, United States
Mayo Clinic - PPDS, Rochester, Minnesota, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07015190 on ClinicalTrials.gov

Other trials for Uveal melanoma

Additional recruiting or active studies for the same condition.

See all trials for Uveal melanoma →

← Back to all trials